Related references
Note: Only part of the references are listed.Efficacy of quadrivalent human papillomavirus vaccine against persistent infection and genital disease in Chinese women: A randomized, placebo-controlled trial with 78-month follow-up
Lihui Wei et al.
VACCINE (2019)
Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland: retrospective population study
Tim Palmer et al.
BMJ-BRITISH MEDICAL JOURNAL (2019)
Clinical course of untreated cervical intraepithelial neoplasia grade 2 under active surveillance: systematic review and meta-analysis
Karoliina Tainio et al.
BMJ-BRITISH MEDICAL JOURNAL (2018)
Clinical course of untreated cervical intraepithelial neoplasia grade 2 under active surveillance: systematic review and meta-analysis
Karoliina Tainio et al.
BMJ-BRITISH MEDICAL JOURNAL (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
The Cochrane HPV vaccine review was incomplete and ignored important evidence of bias
Lars Jorgensen et al.
BMJ EVIDENCE-BASED MEDICINE (2018)
Efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine in Chinese women aged 18-25years: event-triggered analysis of a randomized controlled trial
Feng-cai Zhu et al.
CANCER MEDICINE (2017)
Trends in the sexual behaviour of 15-year olds in Scotland: 2002-14
Fergus G. Neville et al.
EUROPEAN JOURNAL OF PUBLIC HEALTH (2017)
HPV vaccines - A review of the first decade
Diane M. Harper et al.
GYNECOLOGIC ONCOLOGY (2017)
Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial
Warner K. Huh et al.
LANCET (2017)
Multisite HPV16/18 Vaccine Efficacy Against Cervical, Anal, and Oral HPV Infection
Daniel C. Beachler et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Multisite HPV16/18 Vaccine Efficacy Against Cervical, Anal, and Oral HPV Infection
Daniel C. Beachler et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment
Allan Hildesheim et al.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2016)
Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study
Cosette M. Wheeler et al.
LANCET INFECTIOUS DISEASES (2016)
Efficacy of Human Papillomavirus 16 and 18 (HPV-16/18) AS04-Adjuvanted Vaccine against Cervical Infection and Precancer in Young Women: Final Event-Driven Analysis of the Randomized, Double-Blind PATRICIA Trial
Dan Apter et al.
CLINICAL AND VACCINE IMMUNOLOGY (2015)
Are the Two Human Papillomavirus Vaccines Really Similar? A Systematic Review of Available Evidence: Efficacy of the Two Vaccines against HPV
Simona Di Mario et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2015)
Post Hoc Analysis of the PATRICIA Randomized Trial of the Efficacy of Human Papillomavirus Type 16 (HPV-16)/HPV-18 AS04-Adjuvanted Vaccine against Incident and Persistent Infection with Nonvaccine Oncogenic HPV Types Using an Alternative Multiplex Type-Specific PCR Assay for HPV DNA
Frank Struyf et al.
CLINICAL AND VACCINE IMMUNOLOGY (2015)
HPV catch-up vaccination of young women: a systematic review and meta-analysis
Elisabeth Couto et al.
BMC PUBLIC HEALTH (2014)
Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland
K. G. J. Pollock et al.
BRITISH JOURNAL OF CANCER (2014)
Efficacy, immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese women aged 18-25 years: Results from a randomized controlled trial
Feng-cai Zhu et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study
S. Rachel Skinner et al.
LANCET (2014)
Efficacy of the HPV-16/18 vaccine: Final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial
Allan Hildesheim et al.
VACCINE (2014)
Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine Final analysis of a long-term follow-up study up to 9.4 years post-vaccination
Paulo S. Naud et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2014)
Impact of Human Papillomavirus Vaccination on Cervical Cytology Screening, Colposcopy, and Treatment
Ana Cecilia Rodriguez et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2013)
Efficacy of quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine (GARDASIL) in Japanese women aged 1826years
Hiroyuki Yoshikawa et al.
CANCER SCIENCE (2013)
Safety and Immunogenicity of Human Papillomavirus-16/18 AS04-Adjuvanted Vaccine: A Randomized Trial in 10-25-Year-Old HIV-Seronegative African Girls and Young Women
Papa Salif Sow et al.
JOURNAL OF INFECTIOUS DISEASES (2013)
HPV vaccination programs have not been shown to be cost-effective in countries with comprehensive Pap screening and surgery
Judy Wilyman
INFECTIOUS AGENTS AND CANCER (2013)
Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18
A. Szarewski et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Occurrence of vaccine and non-vaccine human papillomavirus types in adolescent Finnish females 4 years post-vaccination
Johanna Palmroth et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
The 2010 Global Proficiency Study of Human Papillomavirus Genotyping in Vaccinology
Carina Eklund et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2012)
Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial
Matti Lehtinen et al.
LANCET ONCOLOGY (2012)
Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial
Cosette M. Wheeler et al.
LANCET ONCOLOGY (2012)
Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine up to 8.4 years of follow-up
Cecilia M. Roteli-Martins et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2012)
End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age
X. Castellsague et al.
BRITISH JOURNAL OF CANCER (2011)
Proof-of-Principle Evaluation of the Efficacy of Fewer Than Three Doses of a Bivalent HPV16/18 Vaccine
Aimee R. Kreimer et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Serotype replacement in disease after pneumococcal vaccination
Daniel M. Weinberger et al.
LANCET (2011)
Prevention of Persistent Human Papillomavirus Infection by an HPV16/18 Vaccine: A Community-Based Randomized Clinical Trial in Guanacaste, Costa Rica
Rolando Herrero et al.
CANCER DISCOVERY (2011)
Efficacy of Human Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Japanese Women Aged 20 to 25 Years Interim Analysis of a Phase 2 Double-Blind, Randomized, Controlled Trial
Ryo Konno et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2010)
Efficacy of Human Papillomavirus Type 16/18 AS04-Adjuvanted Vaccine in Japanese Women Aged 20 to 25 Years
Ryo Konno et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2010)
Long-term Absolute Risk of Cervical Intraepithelial Neoplasia Grade 3 or Worse Following Human Papillomavirus Infection: Role of Persistence
Susanne K. Kjaer et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Impact of Human Papillomavirus (HPV)-6/11/16/18 Vaccine on All HPV-Associated Genital Diseases in Young Women
Nubia Munoz et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Sustained efficacy and immunogenicity of the HPV-16/18 ASO4-adjuvanted vaccine up to 7.3 years in young adult women
N. De Carvalho et al.
VACCINE (2010)
The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV-Naive Women Aged 16-26 Years
Darron R. Brown et al.
JOURNAL OF INFECTIOUS DISEASES (2009)
Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years
B. Romanowski et al.
LANCET (2009)
Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial
Nubia Munoz et al.
LANCET (2009)
Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women
J. Paovonen et al.
LANCET (2009)
Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections
Ana Cecilia Rodriguez et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Human papillomavirus vaccination - Reasons for caution
Charlotte J. Haug
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection
Luisa L. Villa et al.
JOURNAL OF INFECTIOUS DISEASES (2007)
CIN2 is a much less reproducible and less valid diagnosis than CIN3: Results from a histological review of population-based cervical samples
Joseph D. Carreon et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2007)
Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: A meta-analysis update
Jennifer S. Smith et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women:: an interim analysis of a phase III double-blind, randomised controlled trial
Jorma Paavonen et al.
LANCET (2007)
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases
Suzanne M. Garland et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up
L. L. Villa et al.
BRITISH JOURNAL OF CANCER (2006)
Sustained efficacy up to 4-5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial
DM Harper et al.
LANCET (2006)
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial
LL Villa et al.
LANCET ONCOLOGY (2005)
Efficacy and other milestones for human papillomavirus vaccine introduction
SR Pagliusi et al.
VACCINE (2004)
The cervical cancer epidemic that screening has prevented in the UK
J Peto et al.
LANCET (2004)
Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial
DM Harper et al.
LANCET (2004)
Share Paper
